Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090207
Status:
COMPLETED
Last Update Posted:
2017-04-24
First Post:
2004-08-25
Brief Title:
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting CINV Associated With Highly Emetogenic Chemotherapy 0869-801COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Randomized Double-Blind Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Safety Tolerability and Efficacy of Aprepitant Regimen Compared to Ondansetron Regimen for the Prevention of Chemotherapy Induced Nausea and Vomiting CINV Associated With High Dose Cisplatin in Cycle 1
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting CINV in patients with confirmed solid tumors who will be treated with a chemotherapy regimen that includes cisplatin The study will evaluate the investigational drug for the treatment of CINV during the first cycle of treatment with cisplatin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_005 | None | None | None |